FJ Manzano Lista

Background Apremilast is the first oral selective inhibitor of phosphodiesterase 4 (PDE4) indicated for adults with active psoriatic arthritis (PsA) and moderate to severe plaque psoriasis (Pso). Pso and PsA are chronic disorders with significant morbidity, and patients experience diminished health related quality of life (QoL). Purpose The primary objective was to assess changes in QoL and satisfaction of patients starting treatment with apremilast.

Background Abiraterone acetate (AB) and enzalutamide (EZ) are two agents involved in the inhibition of androgen biosynthesis by blocking androgen receptors, and are used to treat prostate adenocarcinoma (AP) in castration resistant patients before and after progression to docetaxel. Purpose To study the effectiveness and safety of AB and EZ as secondline treatmens after docetaxel in patients with unresectable castration resistant AP resistant to docetaxel.

Background Patients with inflammatory bowel disease (IBD) are at risk for iron deficiency. Absorption of orally given iron may be impaired by intestinal inflammation, and treatment with oral iron may aggravate intestinal inflammation. The treatment of iron deficiency anaemia with IBD is a particular challenge and often insufficient. Purpose To describe the effectiveness and safety of intravenous ferric carboxymaltose (FCM) in IBD adult patients.